This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
这位康耐视分析师不再看好;以下是周二的前5个降级
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
华尔街顶级分析师改变了对这些顶级公司的展望。如需查看包括升级和降级在内的所有分析师评级变化的完整视图,请参阅我们的分析师评级页面。
- Deutsche Bank analyst Bryan Keane downgraded the rating for Marqeta, Inc. (NASDAQ:MQ) from Buy to Hold and lowered the price target from $9 to $4. Marqeta shares closed at $5.95 on Monday. See how other analysts view this stock.
- Truist Securities analyst Jamie Cook downgraded Cognex Corporation (NASDAQ:CGNX) from Buy to Hold and slashed the price target from $46 to $43. Cognex shares closed at $40.85 on Monday. See how other analysts view this stock.
- JMP Securities analyst Reni Benjamin downgraded the rating for Sana Biotechnology, Inc. (NASDAQ:SANA) from Market Outperform to Market Perform. Sana Biotechnology shares closed at $3.76 on Monday. See how other analysts view this stock.
- JP Morgan analyst Tessa Romero downgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) from Overweight to Neutral and lowered the price target from $18 to $15. Neumora Therapeutics shares closed at $11.71 on Monday. See how other analysts view this stock.
- Leerink Partners analyst Christopher Liu downgraded the rating for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) from Outperform to Market Perform and lowered the price target from $41 to $27. IDEAYA Biosciences shares closed at $30.00 on Monday. See how other analysts view this stock.
- 德意志银行分析师Bryan Keane将Marqeta, Inc. (纳斯达克:MQ)的评级从买入降级为持有,并将价格目标从$9降至$4。Marqeta股价周一收盘价为$5.95。看看其他分析师如何看待这只股票。
- Truist证券分析师Jamie Cook将Cognex Corporation (纳斯达克:CGNX)的评级从买入降级为持有,并将价格目标从$46下调至$43。Cognex股价周一收盘价为$40.85。看看其他分析师如何看待这只股票。
- JMP证券分析师Reni Benjamin将Sana Biotechnology, Inc. (纳斯达克:SANA)的评级从市场表现优异降级为市场表现。Sana Biotechnology股价周一收盘价为$3.76。看看其他分析师如何看待这只股票。
- 摩根大通分析师Tessa Romero将Neumora Therapeutics, Inc. (纳斯达克:NMRA)的评级从超重降级为中立,并将价格目标从$18下调至$15。Neumora Therapeutics股价周一收盘价为$11.71。看看其他分析师如何看待这只股票。
- Leerink Partners分析师Christopher Liu将IDEAYA Biosciences, Inc. (纳斯达克:IDYA)的评级从表现优异降级为市场表现,并将价格目标从$41下调至$27。IDEAYA Biosciences股价周一收盘价为$30.00。看看其他分析师如何看待这只股票。
Considering buying CGNX stock? Here's what analysts think:
考虑购买CGNX股票吗?以下是分析师的看法:
Read This Next:
Read This Next:
- Top 3 Health Care Stocks You'll Regret Missing In November
- 11月你会后悔错过的前三家医疗保健股票